Enva 10 mg (Lenvatinib) Capsule | Multiple Receptor Tyrosine Kinase Inhibitor (TKI)

Medically Reviewed by Dr. Salma Elreedy, MD (Oncology)

Last Updated: March 27, 2026

Classification: Prescription-Only Medicine (POM)

Prescription-Only Notice: Enva 10 mg (Lenvatinib) is a highly potent antineoplastic agent. It must be prescribed, administered, and monitored exclusively by a board-certified medical oncologist. Do not initiate, alter, or discontinue this medication without direct clinical authorization and rigorous systemic monitoring.

Enva 10 mg contains 10 mg of the active pharmaceutical ingredient Lenvatinib. It is an orally administered, targeted antineoplastic therapy classified as a multiple receptor tyrosine kinase inhibitor (TKI). Enva is utilized to treat aggressive, advanced-stage malignancies, primarily focusing on cancers of the liver, kidneys, thyroid, and endometrium. Unlike standard cytotoxic chemotherapy, Lenvatinib exhibits potent anti-angiogenic properties—meaning it actively starves tumors by cutting off their blood supply while simultaneously disrupting the intracellular signals that command the cancer cells to multiply.

FDA approved Clinica Data about Enva 10 mg (Lenvatinib)

Who is the specific candidate for Enva (Lenvatinib)?

Enva is indicated for adult patients across four primary, advanced clinical settings according to the FDA approval data:

1. Hepatocellular Carcinoma (HCC): First-line treatment for patients with unresectable liver cancer.

2. Differentiated Thyroid Cancer (DTC): For locally recurrent or metastatic, progressive DTC that no longer responds to radioactive iodine therapy (RAI-refractory).

3. Renal Cell Carcinoma (RCC): First-line treatment for advanced kidney cancer (in combination with pembrolizumab), or for previously treated RCC (in combination with everolimus).

4. Endometrial Carcinoma: For advanced cases that are not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), utilized in combination with pembrolizumab following prior systemic therapy.

How does Lenvatinib work at the molecular level?

Tumors need a dedicated blood supply to grow and metastasize. They achieve this by releasing growth factors (like VEGF) that stimulate the formation of new blood vessels—a process called angiogenesis.

Lenvatinib is a multi-kinase inhibitor. It simultaneously blocks several critical receptors on the surface of both tumor cells and surrounding blood vessel cells, specifically targeting VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. By severely inhibiting these pathways, Enva 10 mg dismantles the tumor’s vascular network and directly halts cancer cell proliferation.

**

What are the strict dosage and administration protocols?

Because Enva 10 mg treats multiple cancer types, the dosage protocol varies heavily based on the specific indication:

• DTC: 24 mg once daily.

• RCC & Endometrial Carcinoma: 20 mg once daily (in combination therapies).

• HCC: Weight-based dosing. 12 mg once daily for patients ≥60 kg, or 8 mg once daily for patients <60 kg.

• Administration: Take once daily at the same time, with or without food. Swallow capsules whole.

• Missed Doses: If you miss a dose, take it as soon as you remember. However, if your next dose is due in less than 12 hours, skip the missed dose.

What is the expected safety profile and how are side effects managed?

• Highly Common (>20%): Hypertension (high blood pressure), diarrhea, fatigue, decreased appetite, weight loss, and palmar-plantar erythrodysesthesia (hand-foot syndrome).

  • Actionable Advice: Blood pressure spikes are almost guaranteed due to the drug’s anti-angiogenic nature. You must monitor your BP daily at home. For hand-foot syndrome (redness/peeling on palms and soles), apply thick, urea-based creams daily and avoid tight footwear or friction.

• Severe Adverse Events: * Hepatotoxicity & Renal Failure: Requires strict blood monitoring.

  • GI Perforation & Fistula: Rare but life-threatening tearing of the stomach or intestines.

  • Arterial Thromboembolic Events: Increased risk of heart attacks or strokes.

What is the clinical trial integrity behind Lenvatinib?

The global approval of Lenvatinib is supported by highly respected, peer-reviewed clinical trials:

• The SELECT Trial (NEJM): In radioactive iodine-refractory DTC, Lenvatinib demonstrated a dramatic Progression-Free Survival (PFS) of 18.3 months compared to just 3.6 months for placebo.

• The REFLECT Trial (The Lancet): In unresectable HCC, Lenvatinib proved statistically non-inferior to the previous standard-of-care (sorafenib) for Overall Survival (OS), while demonstrating significantly higher Objective Response Rates (ORR) and prolonged PFS.

• The CLEAR Trial (NEJM): Established Lenvatinib plus pembrolizumab as a highly efficacious first-line therapy for advanced RCC, significantly improving survival outcomes over sunitinib.

Precautions & Special Populations

• Pregnancy & Lactation: Lenvatinib causes severe embryo-fetal toxicity. Female patients of reproductive potential must use highly effective contraception during treatment and for at least 30 days following the final dose. Breastfeeding is strictly contraindicated during therapy and for 1 week after the last dose.

• Pediatric & Geriatric Populations: Safety and efficacy in pediatric patients have not been established. Geriatric patients (65 and older) generally tolerate the drug well, though they experience a statistically higher incidence of severe hypertension and fatigue requiring dose modifications.

• Renal & Hepatic Impairment: Patients with severe renal impairment or severe hepatic impairment require significantly reduced starting doses (e.g., 14 mg for DTC instead of 24 mg).

• Storage Requirements: Enva 10 mg must be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F). Store in the original blister packaging to protect from moisture.

Manufacturer Trust & Global Access

Manufacturer Quality Assurance & Regulatory Approval: Enva 10 mg is manufactured by Techno Drugs LTD, a premier pharmaceutical entity based in Bangladesh, and holds full approval from the Directorate General of Drug Administration (DGDA). The manufacturing facility operates in strict adherence to WHO-GMP (World Health Organization – Good Manufacturing Practices) guidelines. Through rigorous pharmacokinetic testing, Techno Drugs LTD ensures that Enva delivers the exact identical Active Pharmaceutical Ingredient (API), structural stability, and clinical efficacy as the innovator brand, Lenvima.

Pharmacoeconomic Impact: Advanced solid tumors necessitate prolonged, continuous targeted therapy. By offering a structurally identical, highly regulated generic alternative, Enva significantly mitigates the crisis of financial toxicity, enabling patients to maintain critical treatment adherence without suffering catastrophic financial ruin.

Global Access & Named Patient Importation: For patients residing in jurisdictions where generic Lenvatinib is not locally approved or financially accessible, Enva may be procured via “Named Patient” import regulations. Many global health ministries permit individuals to legally import life-saving prescription medications for personal use, provided they hold a valid prescription and a formal Letter of Medical Necessity from a board-certified oncologist. Patients must strictly adhere to their local customs regulations prior to procurement.

People Also Ask

Why is monitoring my blood pressure so important?

Lenvatinib restricts blood vessel growth, which directly causes blood vessels to constrict. This leads to rapid, severe hypertension in most patients. Uncontrolled high blood pressure can cause strokes or heart attacks, requiring immediate medical management.

Can I take Enva 10 mg if I have trouble swallowing capsules?

Yes. You can dissolve Enva capsules in a small glass of water or apple juice. Leave the capsules in the liquid for 10 minutes, stir for 3 minutes, swallow the mixture, and then rinse the glass with more water and drink it to ensure the full dose is taken.

Will this medication cause me to lose my hair?

Complete hair loss (alopecia) is rare with targeted therapies like Lenvatinib. However, mild to moderate hair thinning or changes in hair texture are frequently reported side effects.

Why do I need regular urine tests?

Enva can cause proteinuria, a condition where your kidneys leak excessive protein into your urine due to the drug’s effect on vascular structures. Routine urinalysis is required to monitor your kidney function.

How should I prepare for a scheduled surgery?

Because Enva strongly inhibits angiogenesis (the formation of new blood vessels), it severely impairs wound healing. You must stop taking this medication at least one week prior to any planned surgery or dental procedure.

Does Enva interact with my other medications?

Lenvatinib does not heavily utilize the CYP3A4 liver enzymes, meaning it has fewer interactions than many other TKIs. However, you must inform your doctor about all supplements and medications, especially blood pressure drugs and QT-prolonging agents.

Is Enva a form of immunotherapy?

No. Enva is a targeted kinase inhibitor. However, it is frequently prescribed in combination with immunotherapies like Pembrolizumab (Keytruda) for kidney and endometrial cancers to create a dual-attack on the tumor.

What is hand-foot syndrome?

It is a common dermatological reaction causing severe redness, swelling, pain, and peeling on the palms of your hands and soles of your feet. Use thick moisturizers daily and avoid hot water to prevent blistering.

Can I drink alcohol while taking this medication?

While there is no direct chemical contraindication, alcohol stresses the liver and worsens dehydration. Because Enva 10 mg carries risks of hepatotoxicity and severe diarrhea, avoiding alcohol is strongly recommended by oncologists.

What happens if the medication causes severe diarrhea?

Do not ignore it. Severe diarrhea causes dangerous dehydration and kidney damage. Your oncologist will likely prescribe an anti-diarrheal like loperamide. If it persists, your doctor may temporarily pause or reduce your Enva dosage.

General Medical Disclaimer: The pharmacological and clinical data provided below is for educational and informational purposes only and does not constitute medical advice.